Prescription Drug Businesses

Shionogi's core ethical drug business accounts for more than ninety percent of its total net sales.Its MRs (medical representatives) are providing accurate information in accordance with evidence-based medicine (EBM) for the correct use of drugs that correspond to the diversifying and complex needs of healthcare practitioners as patients and healthcare providers.

Domestic Prescription Drug Businesses

Shionogi has been focusing on the 3 therapeutic areas of metabolic syndrome, infectious diseases and pain. Shionogi plans to concentrate on 8 new products including the hyperlipidemia treatment Crestor, the hypertension treatment Irbetan and antidepressant Cymbalta and provides information on the proper use of pharmaceuticals, and contributes to the treatment by maximizing product values.

Global Development

Shionogi is striving to increase its sales in the US market through US-based group company Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.). Shionogi’s overseas clinical trials for a treatment for obesity and an anti-HIV agent are advancing smoothly to new stages. Shionogi is globalizing its operations under its 3rd medium-term business plan. In the EU, Shionogi plans to establish a development foothold and select business partners. Shionogi also plans to establish a development and business foothold in Asia.

Consumer Health Care Businesses

Shionogi will utilize know-how accumulated through its prescription drugs business to help to promote self-medication by consumers.

Main Brands

To choose the most appropriate product for a given situation SEDES brand
Vitamin compounds POPON brand
Cold remedies PYLON brand
Denture products CORRECT brand

Newly launched products in 2009

To help relieve muscular fatigue POPON B Fresh
To help relieve eye fatigue POPON PUMERI
Cold remedies containing Maoto extract PYLON MX
Serum hyperlipidemia treatment LOCUSTA
Contains crude drugs RESFINA

Diagnostics

Our leading diagnostic drug is a reagent used in the measurement of blood BNP (brain natriuretic peptide). The blood BNP test is a useful indicator for reference when diagnosing and assessing cardiac insufficiency. Because it allows the detection of even extremely mild coronary disorders from an early stage‚ its use is expanding to include not only heart specialists‚ but also general internists‚ as well as in health screening and physical examinations. It is also starting to be used overseas.

In the allergy area‚ HRT Shionogi reagent‚ which can detect isolation of histamine and Allerport TARC, which measures serum levels of TARC‚ are attracting specialists' attention. Especially, the serum levels of TARC rises in step with atopic dermatitis symptoms, therefore, Allerport TARC enables the evaluation of the severity of atopic dermatitis symptoms and confirmation of the effect of medicine.

Shionogi aims to contribute to people’s health by providing diagnostic products including those that are useful in diagnosing, assessing and predicting clinical conditions, as well as prescription drugs.